It was not possible to focus on subgroups delineated by ethnicity: by which baseline breast cancer risk, breast cancer mortality, and MHT use are reported to vary.16 Furthermore, the impact of carrying pathogenic variants in breast cancer susceptibility genes such as BRCA1 and BRCA2 was not considered, but such women would typically be managed in clinical genetics clinics. This evidence concerns the gene BRCA1 and breast carcinoma.